Initial interim safety, tolerability, biomarker, and preliminary efficacy data expected in Q1 2026 – MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or ...

Boca Raton, Florida, July 31, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it will host a ...

Launch preparations underway ahead of U.S. PDUFA goal date of September 7, 2025. The sNDA for PYRUKYND for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent ...

U.S. Patent No. 12,202,873 – Superagonists, Partial Agonists and Antagonists of IL-2. Also granted in Switzerland, China, Germany, France, United Kingdom, India, and Japan and allowed in Canada with ...

Allen Davidoff, CEO of XORTX stated, “With additional interest in the LIFE offering (see news release of June 26 and July 22, 2025) from non-Canadian investors, XORTX has undertaken this small private ...

Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for ...

Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial ...

The opening of the new headquarters is a key milestone in PL BioScience’s long-term strategy to deliver high-quality cell culture supplements to customers and meet increasing global demand for its ...

With its combination of expert care, affordable pricing, and the allure of a vibrant cultural experience, Mexico continues to ...

CrazyBulk has long been recognized as a leader in natural, legal performance supplements. In 2025, the brand has solidified ...

Fagron delivers strong performance with 11% topline growth and 12% increase in REBITDA for H1 2025 Fagron, the leading global player in pharmaceutical compounding today publishes its first half ...

In 2025, sales are anticipated to grow by a high single-digit percentage at CER (previously mid-to-high single-digit). Sanofi confirms the expectation of a strong business EPS rebound with growth at a ...